Citation Impact
Citing Papers
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN
2013
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
2012
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors
2010
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
2011 Standout
Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir
2008
Therapeutic potential of resveratrol: the in vivo evidence
2006 Standout
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
2007 StandoutNobel
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
2005
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin 1 1Edited by R. Huber
2000
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
1995 Standout
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
1999 Standout
Multistage Nanoparticles for Improved Delivery into Tumor Tissue
2012 StandoutNobel
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
2007 Standout
Structural Basis of the Drug-binding Specificity of Human Serum Albumin
2005 Standout
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Paclitaxel (Taxol)
1995 Standout
A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice
2011
Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity
2009 Standout
Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection
2000
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
2011
HIV-Protease Inhibitors
1998
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
2004
Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates
1999
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
2005
Polymer conjugates as anticancer nanomedicines
2006 Standout
Targeting multidrug resistance in cancer
2006 Standout
Immunity, Inflammation, and Cancer
2010 Standout
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
1995
Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51)
2008
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
2001 Standout
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Lopinavir/Ritonavir
2003
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
2013
Treatment of Relapsed/Refractory Multiple Myeloma
2009
Pathogenesis and treatment of renal failure in multiple myeloma
2008
Considerations in the design and development of transport inhibitors as adjuncts to drug therapy
2003
Cancer immunotherapy comes of age
2011 StandoutNature
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
2020 Standout
Functional Genomic Analysis of C. elegans Molting
2005 StandoutNobel
Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism
2005
Molecular mechanisms of necroptosis: an ordered cellular explosion
2010 Standout
Paclitaxel poliglumex (XYOTAX™, CT-2103): A macromolecular taxane
2005
Microtubules as a target for anticancer drugs
2004 Standout
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model, HepatoPac
2015
Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors
1997
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
2017 Standout
Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens
2015 StandoutNobel
Computational design of orthogonal nucleoside kinases
2010 StandoutNobel
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
Paclitaxel and its formulations
2002 Standout
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration
2006
Fluorine in medicinal chemistry
2007 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
2009
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
2001
Update on the use of cinacalcet in the management of primary hyperparathyroidism.
2012
Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications
2019 Standout
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
Transport, metabolism and elimination mechanisms of anti-HIV agents
1999
Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
2010
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
2007 Standout
Impedance Method for Detecting HIV-1 Protease and Screening For Its Inhibitors Using Ferrocene−Peptide Conjugate/Au Nanoparticle/Single-Walled Carbon Nanotube Modified Electrode
2008
Fluorine Substitution Can Block CYP3A4 Metabolism-Dependent Inhibition: Identification of (S)-N-[1-(4-Fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an Orally Bioavailable KCNQ2 Opener Devoid of CYP3A4 Metabolism-Dependent Inhibition
2003
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Protease Inhibitors: Current Status and Future Prospects
2000
Systemic Antifungal Agents
1998
Ritonavir and saquinavir combination therapy for the treatment of HIV infection
1999
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
2018
Solid-Phase Library Synthesis, Screening, and Selection of Tight-Binding Reduced Peptide Bond Inhibitors of a RecombinantLeishmaniamexicanaCysteine Protease B
2002 StandoutNobel
Metal–Organic Frameworks in Biomedicine
2011 Standout
Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1
2007
Multiple Myeloma
2011 Standout
Taxol Suppresses Dynamics of Individual Microtubules in Living Human Tumor Cells
1999
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
2012
Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein.
1998
Works of Gondi Kumar being referenced
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
2012
In Vitro Metabolism of the HIV-1 Protease Inhibitor ABT-378: Species Comparison and Metabolite Identification
1999
6 alpha-Hydroxytaxol: isolation and identification of the major metabolite of taxol in human liver microsomes.
1994
Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction
1999
Role of drug metabolism in drug discovery and development
2001
In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective
2009
METABOLISM AND DISPOSITION OF CALCIMIMETIC AGENT CINACALCET HCL IN HUMANS AND ANIMAL MODELS
2004
Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus
1998
Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis
2007
Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.
1996
Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation.
1994
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein.
1993
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
1997
Taxol metabolism and disposition in cancer patients.
1995